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Background. Several studies investigated the use of selective serotonin reuptake inhibitors (SSRI) after ischemic stroke to improve
motor recovery. However, little is known about the effects of preexisting psychotropic medication use (PPMU), such as
antidepressants, on a long-term ischemic stroke functional disability. Objective. We sought to determine the prevalence of
PPMU and whether PPMU relates to the long-term clinical outcome in a cohort of patients presenting with acute ischemic
strokes. Methods. We retrospectively analyzed 323 consecutive patients who presented with an acute ischemic stroke in a single
institution between January 2015 and December 2017. Baseline characteristics, functional disability as measured by the modified
Rankin Scale (mRS), and major adverse cardiovascular complications (MACE) within 365 days were recorded. The comparison
groups included a control group of ischemic stroke patients who were not on psychotropic medications before and after the
index ischemic stroke and a second group of poststroke psychotropic medication use (PoMU), which consisted of patients
started on psychotropic medication during the index admission. Results. The prevalence of PPMU in the studied cohort was
21.4% (69/323). There was a greater proportion of females in the PPMU than in the comparison groups (P < 0:001), while
vascular risk factors were similar in all groups, except for an increased presence of posterior circulation infarcts in the PPMU
(37.4% vs. 18.8%, P < 0:001). Among the patients with available 1-year follow-up data (n = 246), we noted significantly greater
improvement in stroke deficits, measured by National Institute of Health Stroke Scale (NIHSS) between PPMU and PoMU
vs. control (3 (0-7) versus 1 (0-4), P = 0:041). The 1-year mRS was worse in PPMU and PoMU compared to the control
group (2 (IQ 1-3) vs. 2 (IQ 0-3) vs. 1 (IQ 0-2), respectively, P = 0:013), but delta mRS reflecting the degree of mRS
improvement showed no significant difference between any PMU and control patients (P = 0:76). There was no statistically
significant difference in MACE. Conclusion. PPMU in ischemic stroke is common; it can be beneficial in ischemic stroke
in the long-term clinical outcome and is not associated with increased risks of MACE.
1. Introduction
Stroke is the third leading cause of worldwide disability [1]
and a leading cause of serious long-term disability in the
US, reducing mobility in more than half of its survivors aged
65 and older [2]. Motor deficits affect up to 82% of patients
after stroke and are associated with decreased quality of life
[3]. Several neurotransmitters, specifically norepinephrine
[4] [5] [6], dopamine [7] [8], and serotonin [9] [10, 11] have
been implicated in the modulation of motor recovery after
brain injury. A meta-analysis of combined animal and
human researches suggests that antidepressants, such as
selective serotonin reuptake inhibitors (SSRI), play a crucial
role in poststroke neurological recovery through its probable
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action on a regenerative process [12]. Subsequently, there has
been an increased interest in the role of psychotropic drugs to
potentially improve poststroke motor recovery [3].
Preexisting psychotropic medication use (PPMU) prior
to the onset of an ischemic stroke on long-term stroke out-
come is unknown. SSRI have been studied in several random-
ized control studies, yielding conflicting results regarding the
effect of the medication on outcomes after an ischemic stroke
[11, 13–15]. Furthermore, the effects of PPMU on acute
stroke severity and poststroke outcome have not been well
studied. To our knowledge, there has been only one cohort
study that investigated the association between SSRI use
prior to an ischemic stroke and subsequent outcome within
30 days [16].
In the current study, we sought to determine the preva-
lence of PPMU in a cohort of patients presenting with an acute
ischemic stroke and whether PPMU was associated with the
initial stroke severity as assessed by the admission National
Institute of Health Stroke Scale (NIHSS) score. Secondary
objectives were to determine the association between PPMU
with long-term functional disability as assessed on the
modified Rankin Scale (mRS), as well as major adverse cardio-
vascular events (MACE).
2. Methods
2.1. Study Cohort. The study was approved by the local Insti-
tutional Review Board, and a Health Insurance Portability
and Accountability Act waiver of informed consent was
approved. We retrospectively analyzed prospectively accrued
adult patients (greater than age 18 years) who were evaluated
at the University of Massachusetts Medical Center between
January 2015 and December 2017. We followed the Strength-
ening the Reporting of Observational Studies in Epidemiol-
ogy guidelines (http://www.strobe-statement.org) [17].
2.2. Definitions. We defined ischemic stroke as an episode of
neurological dysfunction due to a focal CNS infarction,
attributable to ischemia [18].
Psychotropic medications were defined as drugs used to
treat psychiatric disorders [19]. The specific psychotropic
medications examined in this study included drugs that target
dopaminergic, norepinephrinergic, and serotonergic neuro-
transmitters, including antidepressants (tricyclic antidepres-
sants, SSRIs, serotonin-norepinephrine reuptake inhibitors,
serotonin antagonist and reuptake inhibitors, monoamine
oxidase inhibitors), amphetamines, lithium, and select atypical
antipsychotics (quetiapine, aripiprazole, and ziprasidone for
examples, which may enhance serotonergic transmission) [19].
Based on the use of psychotropic medication before and
after the index stroke, we stratified patients to three groups
(Figure 1): first, preexisting psychotropic medication use
(PPMU), which included patients who were treated with a
psychotropic medication prior to the onset of the acute
ischemic stroke and were continued on them after the index
stroke; second, poststroke psychotropic medication use
(PoMU), which included patients who were started on
psychotropic medication during the index admission; and
third, control, which included patients who were neither
treated with psychotropic medications before nor after the
index stroke. To minimize potential expectation bias, a
subclassification of study groups was carried out blind to any
follow-up data.
A favorable 1-year functional outcome was defined as a
modified Rankin Scale (mRS) score ≤ 2 [20]. We defined
the degree of functional deficit recovery as the difference
between the admission NIHSS minus the 1-year NIHSS score
(delta NIHSS), whereby larger numbers indicate greater
deficit improvement. The mRS assessment in the poststroke
period was assessed by a stroke-trained physician certified
in mRS via in-person. When the mRS was not available, the
mRS was reconstructed from the case description based upon
the mRS criteria [21]. All diagnoses were first established by
treating physicians and then reassessed by a trained vascular
neurologist (D.J.) after independent chart reviews of the
medical records. A double-boarded psychiatrist and neurolo-
gist (A.J.O.) adjudicated uncertain cases, and remaining
discrepancies were resolved by consensus.
2.3. Exclusion. We excluded patients with severe stroke defi-
cits (NIHSS > 20) with expected poor prognosis, substantial
premorbid disability (mRS > 4), patients who died in house
or were discharged to hospice. Patients lost to follow-up were
excluded from our exploratory analyses.
2.4. Data Collection. Patient demographics, comorbidities,
preadmission medications, admission NIHSS, admission
mRS, and imaging data (MRI brain and/or CT head) were
collected for all patients by neurology trained physicians
[22]. All included patients (n = 323) underwent a brain CT.
An additional imaging with brain MRI (n = 301, 93.2%)
was done at the discretion of the treating physician at the
time of the index admission.
2.5. Outcomes. The primary goals were to identify the preva-
lence of PPMU in acute ischemic stroke and its association
with admission stroke severity as graded by NIHSS. For the
purpose of this analysis, we compared PPMU with non-
PPMU (controls + PoMU) patients.
In a subsequent exploratory analysis, we sought to deter-
mine whether psychotropic medication use was associated
with 1-year disability (defined asmRS > 2), delta mRS (degree
of mRS improvement from baseline to 1 year to account for
the degree of prestroke mRS), delta NIHSS (degree of NIHSS
score improvement from baseline to 1 year to account for
potential confounding by indication as patients with worse
acute NIHSS were more likely started on psychotropic
medication), and major adverse cardiac events (MACE) and
its individual components of recurrent nonfatal stroke, nonfa-
tal myocardial infarction, and cardiovascular death. Given
prior clinical trial data suggesting beneficial effect on motor
recovery with PoMU [11], we conducted an additional
exploratory analysis to determine whether any psychotropic
medication use (any PMU, i.e., combined PPMU and PoMU)
was associated with improved 1-year disability and neurolog-
ical deficit recovery (as assessed by the delta NIHSS) at one
year when compared to controls.
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2.6. Statistical Analyses. Data are reported as median
(interquartile range) unless otherwise stated. Univariate
comparisons were performed with χ2, Fisher exact, Mann–
Whitney U tests, and Kruskal Wallis ANOVA on ranks as
appropriate. Two-sided significance tests were used through-
out, and a two-sided P < 0:05 was considered statistically
significant unless stated otherwise. To calculate corrected
levels of significance in cases of multiple comparisons in the
univariate analyses, adjusted significance level was calculated
using the Bonferroni correction. All statistical analyses were
performed using the IBM SPSS Statistics version 20.0.0
(IBM, Armonk, NY).
3. Results
3.1. Study Participants and Prevalence of Psychotropic
Medication Use. Overall, 323 patients fulfilled the study
criteria and were included in the data analysis (Figure 1).
Of these, 69 (21.4%) patients were on PPMU, 28 (8.7%)
patients were on PoMU, and 226 (69.9%) patients served
controls. The details on the used psychotropic medications
stratified by PPMU and PoMU are shown in Table 1.
3.2. Clinical Characteristics Associated with PPMU. The
baseline characteristics of the studied patient population as
stratified by PPMU versus non-PPMU are shown in Table 2.
The prevalence of female gender in PPMU was higher than
in other groups (68.1% vs. 37.4%, P < 0:001). Moreover, the
PPMU group had similar prevalence of preexisting vascular
risk factors compared to the non-PPMU group, including
hypertension, diabetes mellitus, prior history of TIA and
stroke, atrial fibrillation, coronary artery disease, and periph-
eral vascular disease (P > 0:05), and similar use of stroke
prevention medications (P > 0:05).
3.3. Association of PPMU with Initial Stroke Severity.Overall,
baseline characteristics of PPMU and non-PPMU groups
were similar except for a higher preadmission mRS and more
frequent posterior circulation stroke location in PPMU
patients (P < 0:05, each, Table 2). With regard to the initial
stroke severity, we found no significant difference in the
admission NIHSS between PPMU and non-PPMU groups
(median 3 (IQ 1-8.5) vs. 3 (IQ 1-7), P = 0:352). Similarly,
there was no difference in the final infarct volume and length
of hospital stay (P > 0:05, each).
3.4. Exploratory Analysis of 1-Year Outcome Events.A total of
246 (76.2%) patients had 1-year outcome data available for
analysis. There was no significant difference in the propor-
tion of patients lost to follow-up between groups (P > 0:05).
Table 3 depicts the secondary outcome events in the three
defined groups.
We found that the clinical deficit severity as measured by
the NIHSS at one year was significantly worse in PoMU com-
pared to control and PPMU patients, respectively (median
1.5 vs. 0 and 1; P = 0:035). To account for potential con-
founding by indication (i.e., patients with worse acute NIHSS
were more likely started on psychotropic medication), we
also examined the degree of NIHSS improvement from
admission to 1 year (delta NIHSS). In this analysis, there
was a trend towards greater NIHSS improvement between
PPMU and PoMU versus control, though this did not reach
significance (Table 3). In a separate analysis of any PMU
versus control, any PMU patients had an overall greater focal
deficit recovery than controls as assessed by the delta NIHSS
(3 (0-7) versus 1 (0-4), P = 0:041).
When we examined the degree of functional disability as
measured by the mRS, we found that patients in both the
PPMU and PoMU had significantly worse 1-year mRS than
the control group 2 (1–3) vs. 2 (0-3) vs. 1 (0-2), respectively,
P = 0:013). When we accounted for the degree of prestroke
mRS by calculating the degree of mRS improvement from
baseline to 1 year (delta mRS), this effect was attenuated
when compared across all three groups (P = 0:046), and there
Exclude: 103 patients due to NIHSS >20
25 due to preexisting mRS >4 or CMO
status on index admission
Primary analysis (n = 323): prevalence of preadmission psychotropic
medication use and its association with admission stroke severity
(control [n = 226], PPMU [n = 69], PoMU [n = 28]).
Exclude: 77 patients lost to follow-up
Exploratory analysis (n = 246): Association of PPMU and PoMU with
1-year disability, MACE, and mortality (control [n = 168], PPMU
[n = 58], PoMU [n = 20]).
n = 451 adult patients presented to ED with acute ischemic strokes
Figure 1: Patient flow chart.
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was no significant difference between any PMU and control
patients (P = 0:76).
Finally, we found no statistically significant difference
between the 3 groups in the rates of 12-month MACE (recur-
rent nonfatal stroke, nonfatal myocardial infarction, and
cardiovascular death) (P > 0:05, each, Table 3). The results
were not meaningfully different when we compared controls
with any PMU (not shown).
4. Discussion
Our study is important as it addresses the potential associa-
tion between preadmission psychotropic medication use in
ischemic stroke and long-term disability in a select cohort
of patients presenting with ischemic strokes. This is relevant
as psychotropic medication in stroke is becoming more
recognized due to the increasing awareness of psychiatric
complications in strokes and the utilization of psychotropic
medications towards recovery [11–15, 23]. In our study, we
found an association between greater functional deficit recov-
ery and any psychotropic medication use (pre- or poststroke)
in ischemic stroke compared to control, which leads to an
important suggestion that psychotropic medication use may
be beneficial in ischemic stroke. Our data also suggests that
overall median mRS was still favorable (mRS score ≤ 2) for
each group and that psychotropic medication use does not
appear to increase the risks of MACE.
There are important implications related to prepsycho-
tropic medication use in ischemic stroke. Preexisting SSRI
use and poststroke recovery have not been widely studied.
Thus far, there have been two studies, with one study looking
at discharge mRS from the index admission [20] and one
looking at the risk of stroke mortality and morbidity within
30 days [16]. In these studies, pre-SSRI use in ischemic stroke
patients was associated with good clinical outcomes at early
follow-up following acute ischemic stroke and that prestroke
SSRI use was not associated with an increased risk of severe
stroke or mortality within 1 month, respectively. Moreover,
although the initiation of SSRI in an acute ischemic stroke
and its effect on poststroke recovery has been studied in
several randomized control studies, the results are conflicting
[11, 13–15] as only one study with a smaller sample size was
Table 1: Frequency of psychotropic medication use.
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able to demonstrate a positive effect [11]. Future studies may
benefit from evaluating prestroke measures, including pre-
stroke psychotropic medication use as it may potentially
complement other treatment strategies to improve stroke
recovery [20]. Another important implication is the role of
female gender in ischemic stroke and prepsychotropic medi-
cation use. In a pooled analysis of 19,652 patients, women
were observed to have a higher disability and lesser quality
of life following an ischemic stroke compared to men [24].
Furthermore, it is known that women have a higher
prevalence of poststroke depression compared to men [25].
Poststroke depression is a serious and yet common complica-
tion of stroke, with more severe symptoms of poststroke
depression occurring in women, which can be associated
with higher mortality rates [23].
Poststroke recovery is known to involve activation of the
mechanisms for plasticity in adjacent neurons through long-
term potentiation (LTM) [26, 27]. Several neurotransmitters
are known to be involved in LTM and the modulation of
motor recovery after brain injury, including norepinephrine
[6, 28, 29], dopamine [7, 8], and serotonin [9–11]. Further
future prospective studies are needed to investigate the
potential effects of preischemic stroke psychotropic medica-
tions targeting more than one neurotransmitter (such as
Table 2: Patient characteristics.
Characteristics Prepsychotropic use (n = 69) Non-PPMU (control +PoMU) (n = 254) Unadjusted P value
Gender, female 47 (68.1%) 95 (37.4%) <0.001
Age 66 (57-76) 67 (58-78) 0.443
Admission NIHSS 3 (1-8.5) 3 (1-7) 0.352
MRS on index presentation 0 (0-2) 0 (0-0) <0.001
IV tPA on index presentation 12 (17.4%) 62 (24.4%) 0.26
Thrombectomy 9 (13.0%) 25 (9.8%) 0.442
Decompressive craniectomy 1 (1.4%) 7 (2.8%) 0.536
Length of stay 4 (3-7.5) 4 (3-7) 0.731
Stroke volume (ml) 1.4 (1.0-7.0) 1.6 (1.0-13) 0.312
Discharge destination 0.343
Home 32 (46.4%) 115 (45.3%)
Acute rehab 26 (37.7%) 113 (44.5%)
Skilled nursing facility 11 (15.9%) 26 (10.2%)
Preexisting risk factors
HTN 51 (73.9%) 177 (69.7%) 0.494
Dyslipidemia 47 (68.1%) 155 (61.0%) 0.280
DM 23 (33.3%) 75 (29.5%) 0.542
History of TIA/stroke 23 (33.3%) 66 (26.0%) 0.226
Atrial fibrillation 8 (11.6%) 49 (19.3%) 0.137
CAD 16 (23.2%) 54 (21.3%) 0.730
PVD 14 (20.3%) 46 (18.1%) 0.680
Preadmission medications
Statins 42 (60.9%) 121 (47.6%) 0.051
Antihypertensives 47 (68.1%) 156 (61.4%) 0.307
Antidiabetics 17 (24.6%) 58 (22.8%) 0.753
Antiplatelet 31 (44.9%) 122 (48.0%) 0.647
Anticoagulation 5 (7.2%) 18 (7.1%) 0.964
Lesion side 0.756
Right 31 (44.9%) 12 (44.1%)
Left 30 (43.5%) 103 (40.6%)
Both 7 (10.1%) 29 (11.4%)
Lesion circulation 0.001
Anterior 46 (66.7%) 143 (56.3%)
Posterior 13 (18.8%) 95 (37.4%)
Both 9 (13.0%) 7 (2.8%)
Hemorrhagic conversion 6 (8.7%) 22 (8.7%) 0.993
Data are median (IQ range) and n (%).
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SNRI targeting both serotonin and norepinephrine reuptake,
for example) on the effects of long-term poststroke recovery.
The strengths of the study were independent reassess-
ment of the clinical diagnoses by a trained neurologist, addi-
tional adjudication of uncertain cases by a double board-
certified vascular neurologist and psychiatrist, and the case
resolution by a general agreement by the group. An expecta-
tion bias was attempted to be minimized by classifying the
study groups, blind to any follow-up data. Our study limita-
tions are related to the retrospective study design, its
relatively small sample size, and inclusion of the study popu-
lation from a single tertiary care center, which may have
attributed to bias. Another limitation includes lack of specific
duration of the psychotropic medication use history in
PPMU and PoMU. Our use of mRS as the outcome measures
of stroke recovery can be potentially viewed as a limitation.
However, the mRS is well known to be a reliable and valid
measure of functional outcome [30–32] and has been used
in a large, pragmatic clinical trial [13]. Other limitations
include lack of patient reported outcome utilizations, includ-
ing depression screen (e.g., PHQ-2), and lack of a stroke-spe-
cific, performance-based impairment index, such as the Fugl-
Meyer assessment. However, these were impractical due to
the retrospective study design.
5. Conclusion
PPMU in ischemic stroke is common; it can be beneficial in
ischemic stroke in the long-term clinical outcome and is
not associated with increased risks of MACE. Further studies
are warranted to explore the effects of psychotropic medica-
tions in ischemic stroke.
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